OncoMatch/Clinical Trials/NCT07232654
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Is NCT07232654 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Iparomlimab/Tuvonralimab and Cisplatin for locally advanced cervical cancers.
Treatment: Iparomlimab/Tuvonralimab · Cisplatin — This study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Cervical Cancer
Disease stage
Required: Stage T3A-4A (III-IVA) (FIGO 2018)
FIGO 2018 stage T3a-4a (III-IVA), N1 (positive lymph node metastasis on CT/MRI with short-axis ≥1 cm, or PET-CT showing one or more lymph node metastases with SUVmax ≥2.5), M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior treatment with immune checkpoint inhibitors or other tumor immunotherapy
Cannot have received: tumor immunotherapy
Prior treatment with immune checkpoint inhibitors or other tumor immunotherapy
Lab requirements
Blood counts
anc ≥1.5 ×10⁹/l; platelets ≥100 ×10⁹/l; hemoglobin ≥90 g/l (no blood transfusion or growth factor support within 7 days)
Kidney function
crcl ≥50 ml/min (cockcroft-gault formula), urine protein <2+ or 24h <1.0 g
Liver function
total bilirubin ≤1.5×uln; ast and alt ≤2.5×uln
Cardiac function
lvef ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07232654 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor, tumor immunotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage T3A-4A (III-IVA) is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages